Disclaimer: This text was not translated by WHO

3.4. References

  1. Public announcement to TB in vitro diagnostics manufacturers, procurement agencies and national TB programmes on inclusion of WHO prequalification for TB in vitro diagnostics. Geneva: World Health Organization; 2021 (https://extranet.who.int/pqweb/sites/default/files/documents/210211_PublicAnnouncement_TB_%20in-vitro-diagnostics.pdf).
  2. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142–52 (https://pubmed.ncbi.nlm.nih.gov/32058069/).
  3. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129–41 (https://pubmed.ncbi.nlm.nih.gov/32060007/).
  4. McMaster University. GRADEpro GDT [website]. 2020 (https://gradepro.org/).
  5. Starshinova A, Zhuravlev V, Dovgaluk I, Panteleev A, Manina V, Zinchenko U et al. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. International Journal of Mycobacteriology. 2018;7(1):32.
  6. Starshinova A, Zinchenko Y, Istomina E, Basantsova N, Filatov M, Belyaeva E et al. [Diagnosis of latent tuberculosis infection in personnel of various institutions and determination of the risk group for tuberculosis]. Bioprep Prev Diagnosis. Treat. 2019;19:178–84.
  7. Aggerbeck H, Ruhwald M, Hoff ST, Borregaard B, Hellstrom E, Malahleha M et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS One. 2018;13(9):e0204554 (https://www.ncbi.nlm.nih.gov/pubmed/30248152).
  8. Aggerbeck H, Ruhwald M, Hoff S, Tingskov P, Hellstrom E, Malahleha M et al. Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial. Int J Tuberc Lung Dis. 2019;23(1):38–44.
  9. Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med. 2017;5(4):259–68 (https://www.ncbi.nlm.nih.gov/pubmed/28159608).
  10. Hoff ST, Peter JG, Theron G, Pascoe M, Tingskov PN, Aggerbeck H et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J. 2016;47(3):919–28 (https://www.ncbi.nlm.nih.gov/pubmed/26677940).
  11. Streltsova E, Ryzhkova O, Bespalova A. Comparative clinical studies of skin test Diaskintest and Mantoux test in patients with pulmonary tuberculosis. Astrakhan Medical Journal. 2011;6(1):265–70.
  12. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J et al. Predictive value of interferon-y release assays for incident active tuberculosis: a systematic review and meta- analysis. Lancet Infect Dis. 2012;12(1):45–55 (https://pubmed.ncbi.nlm.nih.gov/21846592/).
  13. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P et al. Interferon-y release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189(1):77–87 (https://pubmed.ncbi.nlm.nih.gov/24299555/).
  14. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682–90 (https://pubmed.ncbi.nlm.nih.gov/24835842/).
  15. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M et al. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One. 2011;6(3):e17984 (https://pubmed.ncbi.nlm.nih.gov/21479236/).
  16. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N et al. Quantitative IFN-γ and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016;193(12):1421–8 (https://pubmed.ncbi.nlm.nih.gov/26765255/).
  17. McCarthy KM, Scott LE, Gous N, Tellie M, Venter WD, Stevens WS et al. High incidence of latent tuberculous infection among South African health workers: an urgent call for action. Int J Tuberc Lung Dis. 2015;19(6):647–53 (https://pubmed.ncbi.nlm.nih.gov/25946353/).
  18. Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One. 2017;12(1):e0169539 (https://pubmed.ncbi.nlm.nih.gov/28060926/).
  19. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012 (https://pubmed.ncbi.nlm.nih.gov/21445325/).

Navigation du livre